// App-Quantinova.ai

4078 : Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study.

Researchers

Presenter

  • Renuka V. Iyer

Principal Investigators

  • Adrienne Groman

  • Catherine Grande

  • Tanios S. Bekaii-Saab

  • Wen Wee Ma

  • Usha Malhotra

  • Dan Iancu

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Circulating tumor cells

  • Ephrin type-B receptor 6

Drug/Treatment

  • Capecitabine

  • Bevacizumab

  • Gemcitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01007552

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved